Table 1.

Studies included in the analysis

Study	Patient population	Patients who received tocilizumab, n
ACT-RAY [17]	MTX-IR	552
ACT-STAR [18]	csDMARD-IR	145
ACT-SURE [19]	csDMARD-IR	949
ADACTA [20]	MTX-IR or MTX-intolerant	161
AMBITION [21]	MTX-naïve or MTX-free for ≥6 monthsa	143
BREVACTA [22]	csDMARD-IR	358
COMP-ACT [23]	csDMARD-IR	624
LITHE [24]	MTX-IR	353
OPTION [25]	MTX-IR	194
ROSE [26]	csDMARD-IR	253
SUMMACTA [27]	csDMARD-IR	1070
TOWARD [28]	csDMARD-IR	660
Total	–	5462

^aIncluded patients with previous exposure to MTX who had discontinued MTX for reasons other than toxicity or lack of efficacy. csDMARD-IR: conventional synthetic DMARD inadequate responders; MTX-IR: MTX inadequate responders.